Your browser is no longer supported. Please, upgrade your browser.
BMY Bristol-Myers Squibb Company daily Stock Chart
Bristol-Myers Squibb Company
IndexS&P 500 P/E16.90 EPS (ttm)3.06 Insider Own0.16% Shs Outstand1.63B Perf Week2.89%
Market Cap84.33B Forward P/E11.56 EPS next Y4.47 Insider Trans0.00% Shs Float1.63B Perf Month5.17%
Income5.01B PEG1.74 EPS next Q1.07 Inst Own74.60% Short Float3.53% Perf Quarter-1.75%
Sales22.56B P/S3.74 EPS this Y-10.90% Inst Trans-0.22% Short Ratio3.97 Perf Half Y-14.25%
Book/sh8.36 P/B6.18 EPS next Y6.63% ROA1.10% Target Price56.91 Perf Year-20.93%
Cash/sh4.19 P/C12.35 EPS next 5Y9.69% ROE3.00% 52W Range44.30 - 70.05 Perf YTD-0.60%
Dividend1.64 P/FCF55.37 EPS past 5Y15.30% ROI20.20% 52W High-26.24% Beta0.79
Dividend %3.17% Quick Ratio1.40 Sales past 5Y3.30% Gross Margin71.40% 52W Low16.64% ATR1.15
Employees23700 Current Ratio1.50 Sales Q/Q8.30% Oper. Margin20.00% RSI (14)58.87 Volatility1.98% 2.25%
OptionableYes Debt/Eq0.54 EPS Q/Q128.60% Profit Margin1.70% Rel Volume1.07 Prev Close50.83
ShortableYes LT Debt/Eq0.42 EarningsJan 24 BMO Payout684.10% Avg Volume14.48M Price51.67
Recom2.30 SMA203.74% SMA503.03% SMA200-5.40% Volume15,534,618 Change1.65%
Jan-15-19Upgrade Societe Generale Sell → Buy
Oct-22-18Downgrade Citigroup Buy → Neutral
Oct-09-18Resumed Guggenheim Neutral
Aug-08-18Upgrade Atlantic Equities Underweight → Neutral
Apr-17-18Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-12-18Reiterated Citigroup Buy $78 → $70
Mar-20-18Reiterated JP Morgan Overweight $70 → $75
Feb-15-18Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-30-17Upgrade SunTrust Hold → Buy
Oct-16-17Downgrade Jefferies Buy → Hold
Sep-12-17Downgrade Hilliard Lyons Long-term Buy → Neutral
Dec-19-16Upgrade Jefferies Hold → Buy
Oct-28-16Reiterated Deutsche Bank Hold $59 → $52
Sep-09-16Reiterated Barclays Equal Weight $75 → $65
Aug-11-16Downgrade Berenberg Buy → Hold
Aug-08-16Reiterated Deutsche Bank Hold $68 → $62
Aug-08-16Downgrade Credit Suisse Outperform → Neutral $63
Aug-05-16Downgrade Morgan Stanley Overweight → Equal-Weight
May-23-16Initiated Hilliard Lyons Neutral
Apr-29-16Reiterated UBS Buy $73 → $80
Feb-15-19 09:09PM  Starboard gauges Bristol-Myers shareholder support for Celgene deal Reuters
09:06PM  Starboard gauges Bristol-Myers shareholder support for Celgene deal Reuters
04:12PM  Bristol-Myers Squibb Company -- Moody's announces completion of a periodic review of ratings of Bristol-Myers Squibb Company Moody's
03:15PM  Nektar, Bristol combo drug shows signs of tumor reduction in bladder cancer patients Reuters
02:03PM  Prothena's (PRTA) Q4 Earnings Beat, Revenues Miss Estimates Zacks
09:06AM  Fridays Vital Data: Bristol-Myers Squibb, Intel and Activision Blizzard InvestorPlace
08:42AM  Strength Seen in AstraZeneca (AZN): Stock Soars 9.3% Zacks
Feb-14-19 04:00PM  Opdivo (nivolumab) Plus Yervoy (ipilimumab) Shows Response in Pre-Treated Patients with Metastatic Castration-Resistant Prostate Cancer Business Wire
03:44PM  Johnson & Johnson (JNJ) to Acquire Auris Health for $3.4B Zacks
02:02PM  Zoetis (ZTS) Beats on Q4 Earnings & Sales, Shares Up Zacks
12:58PM  5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings Zacks
10:08AM  Should You Buy Viking Therapeutics After Gilead Drug Failure? InvestorPlace
09:30AM  BMY vs. AZN: Which Stock Is the Better Value Option? Zacks
08:58AM  AstraZeneca's (AZN) Q4 Earnings Beat, New Drugs Drive Sales Zacks
Feb-13-19 03:47PM  Exelixis Grabs 90% of First Place Motley Fool
03:45PM  AEMD: Eventual FDA Cancer Indication Is A Realistic Outcome Zacks Small Cap Research
01:25PM  Exelixis (EXEL) Earnings, Revenues Beat Estimates in Q4 Zacks
11:40AM  Celgene vs. Gilead Stock: Whats the Better Biotech Buy? InvestorPlace
10:28AM  J&J's (JNJ) Depression Treatment Gets FDA Committee's Nod Zacks
08:36AM  5 Tiny Biotech Stocks With Superb Growth Potential Zacks
Feb-12-19 06:29PM  Aduro Initiates Dosing in Phase I Melanoma Study on ADU-S100 Zacks
05:57PM  Bristol-Myers' Sprycel Gets European Nod for Label Expansion Zacks
05:30PM  Seattle Genetics' Adcetris Gets EC Nod for Label Expansion Zacks
10:10AM  Pfizer sBLA for Kidney Cancer Drug Combo Gets Priority Review Zacks
09:11AM  AbbVie Buys Rights to Novel Immunotherapy for Multiple Myeloma Zacks
08:49AM  The Zacks Analyst Blog Highlights: Bristol-Myers, ConocoPhillips, Qualcomm, General Motors and Marathon Zacks
08:04AM  The Daily Biotech Pulse: NASH Disappointment For Gilead, Xeris To Offer Shares Benzinga
Feb-11-19 08:01PM  Merck, Pfizer combo treatment boosts kidney cancer survival Reuters
05:00PM  Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Demonstrates Continued Survival Benefit at 30-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma Business Wire
01:01PM  Top Analyst Reports for Bristol-Myers, ConocoPhillips & Qualcomm Zacks
09:15AM  This is Why Bristol-Myers Squibb (BMY) is a Great Dividend Stock Zacks
08:45AM  3 Reasons Growth Investors Will Love Bristol-Myers (BMY) Zacks
07:30AM  IFM Therapeutics launches new spinout aimed at Parkinson's, lupus and other diseases American City Business Journals
06:59AM  European Commission Approves Bristol-Myers Squibbs Sprycel (dasatinib) in Combination with Chemotherapy for Treatment of Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Business Wire
06:00AM  Big Pharma Wants to Borrow Cash for M&A, but Could Run Into Credit Downgrades
Feb-10-19 09:00AM  Is Celgene a Buy? Motley Fool
Feb-08-19 07:47AM  Alnylam's (ALNY) Q4 Earnings and Revenues Beat Estimates Zacks
Feb-07-19 04:31PM  Exelixis (EXEL) to Report Q4 Earnings: What's in Store? Zacks
06:59AM  Bristol-Myers Squibb to Take Part in Guggenheim Healthcare Talks Idea Forum Business Wire
Feb-06-19 05:52PM  At least four pharma CEOs to testify at Senate drug pricing hearing Reuters
03:35PM  Bristol-Myers Stock Could Get Hit By Donald Trumps Drug-Price Plan
01:33PM  At least four pharma CEOs to testify at Senate drug pricing hearing Reuters
10:18AM featured highlights include: Starbucks, Bristol-Myers, Portland General Electric, Foot Locker and J.B. Hunt Zacks
10:00AM  Kaskela Law LLC Announces Stockholder Investigation of Bristol-Myers Squibb Company - BMY ACCESSWIRE
06:36AM  10 Industries That Haven't Been This Cheap in at Least 5 Years Motley Fool
06:31AM  Boasting A 36% Return On Equity, Is Bristol-Myers Squibb Company (NYSE:BMY) A Top Quality Stock? Simply Wall St.
06:08AM  Winners & Losers from Trump's State of the Union Address Zacks
Feb-05-19 04:06PM  Merck CEO Frazier to testify at Senate drug pricing hearing Reuters
01:00PM  CEO of activist hedge fund Starboard: 'We are certainly interested in the story at Bristol-Myers' CNBC Videos
12:49PM  CEO of activist hedge fund Starboard: 'We are certainly interested in the story at Bristol-Myers' CNBC
11:38AM  Pharma execs will testify before Congress 'one way or another,' US senator says CNBC
10:56AM  There's 'no doubt' Papa John's needs to get better, says CEO CNBC Videos
07:08AM  5 Stocks With Strong Sales Growth Worth Buying Right Now Zacks
05:00AM  "Business is Booming" at Bristol-Myers MoneyShow
Feb-04-19 05:01PM  Here's Why Mirati Therapeutics Jumped 55.8% in January Motley Fool
04:49PM  Stocks Rise Ahead of Alphabet Earnings
04:23PM  Report Says Starboard Value Takes Stake in Bristol-Myers
04:03PM  Papa John's Stock Surges As Starboard Invests $200 Million, CEO Becomes Chairman Investor's Business Daily
02:10PM  An activity targets BMY, GM looks to Brazil & more CNBC Videos
01:58PM  Celgene Highlights What Bristol-Myers Squibb Is Getting Motley Fool
01:53PM  Bristol-Myers Gains After Starboard Takes a Position Bloomberg
01:27PM  Heres What Starboard Might Be Planning for Papa Johns and Bristol-Myers
01:20PM  Faber: Hedge fund Starboard Value has not contacted Bristol-Myers Squibb CNBC Videos
12:47PM  Starboard Investing in Papa John's, Bristol-Myers Squibb Bloomberg
12:12PM  5 of the Best Biotech Stocks to Buy Now InvestorPlace
11:38AM  Jim Cramer on Starboard's Stake in Bristol-Myers Squibb and Papa Johns
09:56AM  Jim Cramer: Tesla, Starboard and Google Earnings
09:18AM  Bristol-Myers Squibb shares pop on report Starboard Value has taken a stake in drugmaker CNBC
Feb-03-19 06:51PM  Starboard Value Snags Stake in Bristol-Myers Squibb, Says Bloomberg
09:01AM  The Results Are In, and It's Clear Celgene Doesn't Need Bristol-Myers Squibb Motley Fool
01:22AM  [$$] Wall St set for $1bn fee bonanza from pharma mega-deal Financial Times
Feb-02-19 03:13PM  Starboard Value Is to Take Stake in Bristol-Myers Squibb Bloomberg
Feb-01-19 12:13PM  Novo Nordisk (NVO) Q4 Earnings Miss Estimates, Revenues Beat Zacks
11:00AM  Merck Pops On Quarterly Beat As Keytruda Sales Jump Despite U.S. Lag Investor's Business Daily
10:15AM  Pharma Catches Another Case Of M&A Fever Benzinga
10:07AM  AVEO Oncology Plunges on Delay in Filing Fotivda NDA With FDA Zacks
09:40AM  Top Ranked Income Stocks to Buy for February 1st Zacks
09:33AM  Merck Stock Gains Because Cancer Drug Brings Rising Earnings
09:15AM  Lilly (LLY) Hits 52-Week High, Can the Run Continue? Zacks
Jan-31-19 03:15PM  Celgene Corporation (CELG) Q4 2018 Earnings Conference Call Transcript Motley Fool
12:57PM  The Eaton Vance Fund Exits Aetna, Bristol Myers
11:46AM  Celgene (CELG) Q4 Earnings Beat Estimates, Revenues Up Y/Y Zacks
07:56AM  Celgene profit beats as psoriasis drug sales surge Reuters
07:55AM  Celgene stock up 0.4% after earnings beat MarketWatch
07:37AM  Celgene posts 16 pct rise in fourth quarter revenue Reuters
Jan-30-19 08:37AM  Novartis 2019 growth outlook leaves investors wanting more Reuters
Jan-29-19 10:55PM  Edited Transcript of BMY earnings conference call or presentation 24-Jan-19 1:30pm GMT Thomson Reuters StreetEvents
10:43AM  Allergan (AGN) Q4 Earnings Beat Estimates, 2019 View Tepid Zacks
10:00AM  Is a Beat in the Cards for Celgene (CELG) in Q4 Earnings? Zacks
Jan-28-19 05:45PM  Bristol-Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know Zacks
05:26PM  Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth Zacks
01:38PM  Pfizer Stock Is at Do-or-Die Spot Ahead of Earnings InvestorPlace
10:19AM  Drug/Biotech Stock Earnings on Jan 29: PFE, AMGN, BIIB & AGN Zacks
10:07AM  The Zacks Analyst Blog Highlights: J&J, Bristol-Myers, Lilly, AbbVie and Merck Zacks
08:42AM  Climate Change Could Hit These Companies Hardest
Jan-27-19 09:03AM  Bristol-Myers Squibb's Q4 Earnings Update Shows Why It Needs Celgene Motley Fool
Jan-26-19 10:05AM  Is Bristol-Myers Squibb a Bargain Now? Motley Fool
06:00AM  Morningstar Runs the Numbers Morningstar
Jan-25-19 12:59PM  US companies turning to term loans for acquisition debt Reuters
12:00PM  Celgene Stock Is Rising After the CEO of AbbVie Ruled Out a Big Deal
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis, an inhibitor targeted at stroke prevention in atrial fibrillation and prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. It has collaboration agreements with Nektar Therapeutics; Illumina, Inc.; Janssen Pharmaceuticals, Inc.; Advantagene, Inc.; Compugen Ltd.; Infinity Pharmaceuticals, Inc.; Tsinghua University; Sirenas; Vedanta Biosciences, Inc.; Mirati Therapeutics, Inc.; and Boston Medical Center. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. The company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BOERNER CHRISTOPHER S.EVP, Chief Commercial OfficerFeb 02Option Exercise0.004,46504,465Feb 05 04:53 PM
Bancroft Charles AEVP & Chief Financial OfficerDec 02Option Exercise0.006,4010206,117Dec 04 04:31 PM
Biondi PaulSVP, Head of Strategy & BDOct 02Option Exercise0.005920592Oct 04 04:56 PM
Dubow AdamChief Compliance & Ethics OffiSep 03Option Exercise0.00797015,495Sep 05 04:49 PM
Santiago Karen MurphyControllerSep 01Option Exercise0.0064104,057Sep 05 04:49 PM
Gordon MurdoEVP, Chief Commercial OfficerAug 01Option Exercise0.001,510050,168Aug 03 05:05 PM
Biondi PaulSVP, Head of Strategy & BDJul 01Option Exercise0.001,46101,461Jul 03 09:24 PM
Caforio GiovanniChairman and CEOMay 05Option Exercise0.008,0400292,822May 08 05:05 PM
Paliwal Dinesh CDirectorApr 30Buy52.404,770249,9488,027May 02 04:05 PM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerApr 03Option Exercise0.0012,367018,267Apr 05 04:37 PM
Caforio GiovanniChairman and CEOMar 10Option Exercise0.00219,2110333,970Mar 13 04:56 PM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0036,044075,370Mar 13 04:56 PM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0020,043086,932Mar 13 04:56 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0034,681053,132Mar 13 04:57 PM
Gordon MurdoEVP, Chief Commercial OfficerMar 10Option Exercise0.0039,235062,028Mar 13 04:55 PM
Santiago Karen MurphyControllerMar 10Option Exercise0.004,40704,456Mar 13 04:55 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0091,3180363,739Mar 13 04:53 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0031,2750136,441Mar 13 04:54 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0068,8960488,677Mar 13 04:54 PM
Bancroft Charles AEVP & Chief Financial OfficerFeb 23Option Exercise22.1437,460829,364302,348Feb 27 04:45 PM